Asthma treatment

http://www.healasthma.com – . Oklahoma Daily (University of Oklahoma) U. Oklahoma professor develops asthma technology ( ) NORMAN, Okla – A University of Oklahoma professor has invented a machine called the breathmeter, which is designed to help diagnose and monitor asthma. Patrick McCann, electrical and computer engineering professor and founder of Ekips Technologies Inc., recently developed the instrument, which measures the concentration of nitric oxide molecules in an asthmatic’s lungs. The molecules are associated with bronchial tube and tissue inflammation endured by those with asthma,… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at Deutsche Bank Securities st Annual Health Care Conference – Final UNIDENTIFIED SPEAKER Good morning. Our next presenting company is Adams Respiratory Therapeutics. In my career as an analyst I really haven’t seen a company like this before. Very unique story. A company that’s basically come out of nowhere and already in the land of giants has captured – is now one of the biggest franchises in the whole over the counter market. And it’s no surprise their IPO is one of the most successful of the last couple years. And it… PART D How’s it doing? Most report no problems Some recipients having difficulty with cost, meds ///// Four months into Medicare’s new prescription drug benefit, more than percent of seniors who have used it at least once say they have had no problems getting their medicines. That’s according to a survey released last week by the Kaiser Family Foundation, a leading health-policy organization that has tracked the new Medicare Part D benefit since before it took effect Jan. .It’s good… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference – Final OPERATOR Good morning and welcome to the Adams Day. Leading specialty pharmaceutical company focusing on the OTC and prescription, respiratory therapeutics market. Kicking off the presentation for the company this morning is Janet Barth, Adams’ VP of Investor Relations. JANET BARTH, EXECUTIVE DIRECTOR, INVESTOR AND PUBLIC RELATIONS, ADAMS RESPIRATORY THERAPEUTICS Thank you Elliot and good morning everyone. Today I’m joined by Mike Valentino our President and… . FD (FAIR DISCLOSURE) WIRE – Event Brief of Full Year Teva Pharmaceutical Earnings Conference Call – Final PARTICIPANTS . Kevin Manix, Teva Pharmaceutical Industries, Director IR . Israel Makov, Teva Pharmaceutical Industries, President & CEO . Dan Suesskind, Teva Pharmaceutical Industries, CFO . Rich Silver, Lehman Brothers, Analyst . Demi Samsoulis, UBS, Analyst . George Barrett, Teva Pharmaceutical Industries, President & CEO Teva North America . Ken Cacciatore, Cowen, Analyst . Bill Marth, Teva Pharmaceutical Industries, President & CEO… . FD (FAIR DISCLOSURE) WIRE – Full Year Teva Pharmaceutical Earnings Conference Call – Final OPERATOR Welcome to the Teva fourth-quarter and full-year results conference call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (OPERATOR INSTRUCTIONS). As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mr. Kevin Manix, Director of Investor Relations for Teva. Thank you, Mr. Manix, you begin. KEVIN MANIX, DIRECTOR IR, TEVA PHARMACEUTICAL… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at Deutsche Bank Securities Small Cap Growth Conference – Final UNIDENTIFIED COMPANY REPRESENTATIVE Our next company to present this morning is Adams Respiratory. They’re a new story, given that the company’s IPO was actually one of the best IPOs of last year. Stock was up in access of %. The company is somewhat unique in specialty pharma as it’s flagship product, Mucinex, is primarily promoted directly through consumer advertising rather than through specialty physicians. So anyway, here to tell us more about the… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at Deutsche Bank Securities Small Cap Growth Conference – Final UNIDENTIFIED COMPANY REPRESENTATIVE Our next company to present this morning is Adams Respiratory. They’re a new story, given that the company’s IPO was actually one of the best IPOs of last year. Stock was up in access of %. The company is somewhat unique in specialty pharma as it’s flagship product, Mucinex, is primarily promoted directly through consumer advertising rather than through specialty physicians. So anyway, here to tell us more about the… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at Deutsche Bank Securities Small Cap Growth Conference – Final UNIDENTIFIED COMPANY REPRESENTATIVE Our next company to present this morning is Adams Respiratory. They’re a new story, given that the company’s IPO was actually one of the best IPOs of last year. Stock was up in access of %. The company is somewhat unique in specialty pharma as it’s flagship product, Mucinex, is primarily promoted directly through consumer advertising rather than through specialty physicians. So anyway, here to tell us more about the… . FD (FAIR DISCLOSURE) WIRE – Adams Respiratory Therapeutics at Deutsche Bank Securities Small Cap Growth Conference – Final UNIDENTIFIED COMPANY REPRESENTATIVE Our next company to present this morning is Adams Respiratory. [They're a news story, given that the company's IPO it's one-it was actually one of the best IPOs of last year. Stock was up in access of [ %]. The company is somewhat unique in specialty pharma as it’s flagship product, Mucinex, is primarily promoted directly through [inaudible] advertising rather than through specialty physicians. So anyway,… –